Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Polypeptide having inhibitory effect on novel coronavirus HCoV-EMC/2012 infection and application thereof

A hcov-emc2012, coronavirus technology, applied in the field of recombinant cells, can solve the problem of no effective specific drugs for the new coronavirus HCoV-EMC, and achieve the effect of filling the international gap

Active Publication Date: 2014-10-01
FUDAN UNIV
View PDF2 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At the same time, there is no effective specific drug for the new coronavirus HCoV-EMC 2012, and the existing treatment measures are only supportive treatment for the symptoms of patients.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polypeptide having inhibitory effect on novel coronavirus HCoV-EMC/2012 infection and application thereof
  • Polypeptide having inhibitory effect on novel coronavirus HCoV-EMC/2012 infection and application thereof
  • Polypeptide having inhibitory effect on novel coronavirus HCoV-EMC/2012 infection and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Example 1 The polypeptide enters the inhibition experiment on the new coronavirus HcoV-EMC 2012

[0039] The peptides HR1-1, HR1-2, HR1-3, HR1-4, HR1-5, HR2-1, HR2-2 and HR2-3 ( figure 1 Shown) Perform 4-fold gradient dilution; add 100 μl of each sample to a 96-well cell culture plate pre-plated with 50,000 African green monkey kidney cells (Vero cells) per well, incubate at 37°C for 2 hours, then remove the supernatant. Wash the cells twice with PBS, add 100 μl of new coronavirus HCoV-EMC 2012 (10TCID50), incubate at 37°C for 1 hour; then wash the cells twice with PBS. Then add 100 μl sample / well to the 96-well plate for further interaction with the cells. The cells were then cultured at 37°C for 3 days. Record the cytopathic effect (CPE), then add 10 μl MTT to each well. Incubate at 37°C for 4 hours; add 100 μl of 0.01M HCl containing 1% SDS to each well, incubate overnight at 37°C and measure the absorbance at a wavelength of 570nm.

[0040] Anti-virus results such as...

Embodiment 2

[0045] Example 2 Interaction between HR1-5 and HR2-2

[0046] This experiment refers to the document "Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors." (Liu,SW et al. Lancet 363, 938-947, 2004) operating.

[0047]

[0048] 1. Non-denaturing polyacrylamide gel electrophoresis (N-PAGE). Mix HR1 series peptides with HR2 series peptides (final concentration 30μM each), and incubate at 37°C for 30 minutes. Take 5× high pH loading buffer and mix it with 4 times the volume of peptide mixture. Then spot the sample (25 μl per well) in 18% non-denaturing gel (Beijing Tianenze), and conduct electrophoresis at 125V constant voltage for 2 hours at room temperature. Coomassie brilliant blue stain. The results showed that after HR1-5 was mixed with HR2 series peptides, a new peptide was produced ( Figure 4 A). This band is the EMC virus fusion active six-hel...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of biological medicine and provides a polypeptide. The polypeptide contains a sequence as shown in SEQ ID No. 9 and has an inhibitory effect on novel coronavirus HCoV-EMC / 2012 infection. The invention also provides to a nucleic acid molecule coding the polypeptide, related recombinant protein, a nucleic acid molecule, an expression vector and a recombinant cell. A medicine can be prepared from the polypeptide provided by the invention and frequently medically acceptable carrier, excipient or the like for prevention and inhibition of novel coronavirus HCoV-EMC / 2012 infection; and polypeptide can also be combined with other medicines. The invention provides candidate polypeptide medicines for prevention or treatment of novel coronavirus HCoV-EMC / 2012 infection.

Description

technical field [0001] The invention belongs to the field of biomedicine, and relates to a group of polypeptides capable of inhibiting the infection of novel coronavirus HCoV-EMC 2012, as well as nucleic acid molecules encoding the polypeptides, related recombinant proteins, nucleic acid molecules, expression vectors and recombinant cells. Background technique [0002] In 2012, a new type of coronavirus HCoV-EMC 2012 originating from the Middle East has caused many deaths, and the mortality rate was as high as 57%, and the rest of the patients also suffered from severe diseases. Current studies have found that the receptor used by the new coronavirus HCoV-EMC 2012 is different from that used by the SARS coronavirus. Its receptor is dipeptidyl peptidase 4 (DPP4), a widely distributed human cell receptor, thus The virus has a wide range of infectivity to human cells. In addition, the new coronavirus HCoV-EMC 2012 can infect a variety of animals, including bats and pigs, makin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/165C12N15/50C12N15/63A61K39/215A61K48/00A61P31/14C12N5/071
CPCA61K38/00A61K48/00C12N15/63C07K14/165A61K39/215C07K14/005C12N2770/20022C12N2770/20033A61P31/14
Inventor 姜世勃陆路刘奇
Owner FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com